amphetamine has been researched along with Narcolepsy in 43 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Narcolepsy: A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This case report describes a woman with narcolepsy treated with racemic amphetamine (rac-amphetamine) during pregnancy and breastfeeding with follow-up on the infant's development up to 10 months of age." | 7.81 | Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. ( Beck, O; Öhman, I; Sarman, I; Wikner, BN, 2015) |
| "Cataplexy was not affected by amphetamine treatment, but was abolished in two patients when clomipramine was given together with either amphetamine." | 6.64 | Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. ( Fenton, GW; Parkes, JD, 1973) |
| "This case report describes a woman with narcolepsy treated with racemic amphetamine (rac-amphetamine) during pregnancy and breastfeeding with follow-up on the infant's development up to 10 months of age." | 3.81 | Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. ( Beck, O; Öhman, I; Sarman, I; Wikner, BN, 2015) |
| "The excretion of amphetamine in human breast milk was studied in a nursing mother with narcolepsy, who was treated with 20 mg daily of a racemic preparation of amphetamine." | 3.67 | Amphetamine secretion in breast milk. ( Hallberg, M; Rane, A; Steiner, E; Villén, T, 1984) |
| "Cataplexy was not affected by amphetamine treatment, but was abolished in two patients when clomipramine was given together with either amphetamine." | 2.64 | Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. ( Fenton, GW; Parkes, JD, 1973) |
| "Amphetamine was discovered over 100 years ago." | 2.49 | Amphetamine, past and present--a pharmacological and clinical perspective. ( Gosden, J; Heal, DJ; Nutt, DJ; Smith, SL, 2013) |
| "Amphetamine stimulants have been used medically since early in the twentieth century, but they have a high abuse potential and can be neurotoxic." | 2.45 | Potential adverse effects of amphetamine treatment on brain and behavior: a review. ( Berman, SM; Kuczenski, R; London, ED; McCracken, JT, 2009) |
| "Amphetamines evaluated were D- and D,L-amphetamine and methamphetamine." | 2.43 | NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. ( , 2005) |
| "Modafinil may increase wakefulness through activation of noradrenergic and dopaminergic systems, possibly through interaction with the hypocretin/orexin system." | 2.42 | What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. ( Boutrel, B; Koob, GF, 2004) |
| "We found that cataplexy is modulated by a D2-like receptor mechanism, whereas dopamine modulates sleep attacks by a D1-like receptor mechanism." | 1.36 | Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. ( Burgess, CR; Gillis, L; Peever, JH; Tse, G, 2010) |
| "In contrast, the results of cataplexy testing demonstrate that amphetamine (2." | 1.29 | Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. ( Dement, WC; Mignot, E; Nishino, S; Shelton, J; Vaught, J, 1995) |
| "Two subjects with narcoleptic syndrome and three healthy volunteers underwent functional magnetic resonance imaging during the simultaneous presentation of periodic auditory and visual stimuli both before and after administration of amphetamine." | 1.29 | Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome. ( Brammer, M; Bullmore, ET; David, AS; Ellis, C; Howard, RJ; Mellers, JD; Parkes, JD; Simmons, A; Williams, SC; Woodruff, PW, 1996) |
| "NARCOLEPSY IS A DISORDER OF SLEEP CONTROL CHARACTERIZED BY A TETRAD OF SYMPTOMS: sleep attacks, cataplexy, sleep paralysis and hypnagogic hallucinations." | 1.25 | Narcolepsy. ( Foley, A; Murray, TJ, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (60.47) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 5 (11.63) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Perez-Vilar, S | 1 |
| Kempner, ME | 1 |
| Dutcher, SK | 1 |
| Menzin, TJ | 1 |
| Woods, C | 1 |
| Leishear, K | 1 |
| Osterhout, J | 1 |
| Adimadhyam, S | 1 |
| Adereti, M | 1 |
| Carruth, A | 1 |
| Hansbury, A | 1 |
| Sandhu, SK | 1 |
| Lyons, JG | 1 |
| Krief, S | 1 |
| Berrebi-Bertrand, I | 1 |
| Nagmar, I | 1 |
| Giret, M | 1 |
| Belliard, S | 1 |
| Perrin, D | 1 |
| Uguen, M | 1 |
| Robert, P | 1 |
| Lecomte, JM | 1 |
| Schwartz, JC | 1 |
| Finance, O | 1 |
| Ligneau, X | 1 |
| Kim, P | 1 |
| During, E | 1 |
| Miglis, M | 1 |
| Turner, M | 1 |
| Heal, DJ | 1 |
| Smith, SL | 1 |
| Gosden, J | 1 |
| Nutt, DJ | 1 |
| Krishnamurthy, VB | 1 |
| Nallamothu, V | 1 |
| Singareddy, R | 1 |
| Öhman, I | 1 |
| Wikner, BN | 1 |
| Beck, O | 1 |
| Sarman, I | 1 |
| Berman, SM | 1 |
| Kuczenski, R | 1 |
| McCracken, JT | 1 |
| London, ED | 1 |
| Burgess, CR | 1 |
| Tse, G | 1 |
| Gillis, L | 1 |
| Peever, JH | 1 |
| HEYCK, H | 1 |
| CRUMP, GP | 1 |
| ROTH, B | 4 |
| Boutrel, B | 1 |
| Koob, GF | 1 |
| Afanas'ev, IuKh | 1 |
| Steiner, E | 1 |
| Villén, T | 1 |
| Hallberg, M | 1 |
| Rane, A | 1 |
| Parkes, D | 1 |
| Shelton, J | 1 |
| Nishino, S | 2 |
| Vaught, J | 1 |
| Dement, WC | 2 |
| Mignot, E | 2 |
| Howard, RJ | 1 |
| Ellis, C | 1 |
| Bullmore, ET | 1 |
| Brammer, M | 1 |
| Mellers, JD | 1 |
| Woodruff, PW | 1 |
| David, AS | 1 |
| Simmons, A | 1 |
| Williams, SC | 1 |
| Parkes, JD | 4 |
| Fischer, SP | 1 |
| Healzer, JM | 1 |
| Brook, MW | 1 |
| Brock-Utne, JG | 1 |
| Wisor, JP | 1 |
| Sora, I | 1 |
| Uhl, GH | 1 |
| Edgar, DM | 1 |
| Debono, AG | 1 |
| Jenner, P | 1 |
| Walters, J | 1 |
| Siever, L | 1 |
| Kraemer, H | 1 |
| Sack, R | 1 |
| Angwin, P | 1 |
| Berger, P | 1 |
| Zarcone, V | 2 |
| Barchas, J | 1 |
| Brodie, HK | 1 |
| Lange, KW | 1 |
| Faber, J | 3 |
| Nevsímalová, S | 3 |
| Tosovský, J | 3 |
| Osval'd, I | 1 |
| Kuhlo, W | 1 |
| Baldessarini, RJ | 1 |
| Guilleminault, C | 1 |
| Carskadon, M | 1 |
| Fenton, GW | 1 |
| Sigwald, J | 1 |
| Julou, L | 1 |
| Bouttier, D | 1 |
| Thomas, J | 1 |
| Yoss, RE | 1 |
| Pearlman, CA | 1 |
| Greenberg, R | 1 |
| Fenton, G | 1 |
| Struthers, G | 1 |
| Curzon, G | 1 |
| Kantamaneni, BD | 1 |
| Buxton, BH | 1 |
| Record, C | 1 |
| Murray, TJ | 1 |
| Foley, A | 1 |
| Ellinwood, EH | 1 |
| Cohen, S | 1 |
| Hotermans, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| Donor Human Milk for Infants With Neonatal Abstinence Syndrome[NCT02182973] | 12 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102] | Phase 4 | 105 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210] | Phase 4 | 2 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in head circumference from day 1 to day 14 (cm/wk) (NCT02182973)
Timeframe: 2 weeks
| Intervention | cm/wk (Mean) |
|---|---|
| Donor Human Milk | 0.4 |
| Historical Control | 0.6 |
Minimum score:0; Maximum score 13. Higher scores mean more GI distress (NCT02182973)
Timeframe: 2 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Donor Human Milk | 39 |
| Historical Controls | 61 |
Change in weight from study day 1 to study day 14 (grams/day) Weight day 14 - weight day 1 divided by 14 (NCT02182973)
Timeframe: 2 weeks
| Intervention | grams/day (Mean) |
|---|---|
| Donor Human Milk | 19.1 |
| Historical Control | 20.5 |
Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 53.5 |
| Modafinil | 61.0 |
Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -5.67 |
| Modafinil | -8.91 |
(NCT00626210)
Timeframe: 1 month
| Intervention | hours (Median) |
|---|---|
| Modafinil | 9.5 |
10 reviews available for amphetamine and Narcolepsy
| Article | Year |
|---|---|
Amphetamine, past and present--a pharmacological and clinical perspective.
Topics: Adolescent; Adult; Amphetamine; Amphetamine-Related Disorders; Animals; Attention Deficit Disorder w | 2013 |
Potential adverse effects of amphetamine treatment on brain and behavior: a review.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Brain; Central Nervou | 2009 |
What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications.
Topics: Amphetamine; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Cocaine; Dopamine Uptak | 2004 |
NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo | 2005 |
Introduction to the mechanism of action of different treatments of narcolepsy.
Topics: Amphetamine; Brain; Clomipramine; Drug Therapy, Combination; Humans; Imipramine; Narcolepsy | 1994 |
[Narcolepsy].
Topics: Adolescent; Adult; Amphetamine; Cataplexy; Child; Clomipramine; Diagnosis, Differential; Female; Hum | 1990 |
[Nacolepsy an its therapy].
Topics: Amphetamine; Barbiturates; Cataplexy; Drug Tolerance; Electroencephalography; Humans; Imipramine; Mo | 1971 |
Symposium: behavior modification by drugs. I. Pharmacology of the amphetamines.
Topics: Amphetamine; Animals; Arousal; Catecholamines; Central Nervous System; Child; Child, Preschool; Cons | 1972 |
Narcolepsy.
Topics: Adolescent; Adult; Amphetamine; Cataplexy; Child; Diagnosis, Differential; Female; Hallucinations; H | 1973 |
Medical-psychological implications of recent sleep research.
Topics: Adaptation, Psychological; Amphetamine; Barbiturates; Central Nervous System Stimulants; Chloral Hyd | 1970 |
2 trials available for amphetamine and Narcolepsy
| Article | Year |
|---|---|
Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy.
Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Dextroamphetamine; Electroencephalography; Eva | 1973 |
Amphetamine abuse.
Topics: Acetylcholinesterase; Aggression; Amphetamine; Animals; Antisocial Personality Disorder; Behavior, A | 1971 |
31 other studies available for amphetamine and Narcolepsy
| Article | Year |
|---|---|
Switching patterns of immediate-release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15-64 years in the United States, 2013-2019.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Drugs, Generic; Humans; Medicaid; Narcol | 2023 |
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbamates; Corp | 2021 |
A Case of Narcolepsy Type 2 and Postural Tachycardia Syndrome Secondary to Lesions of the Thalamus and Amygdala.
Topics: Adolescent; Adrenergic beta-Antagonists; Amphetamine; Amygdala; Central Nervous System Stimulants; D | 2018 |
The Treatment of Narcolepsy With Amphetamine-Based Stimulant Medications: A Call for Better Understanding.
Topics: Amphetamine; Central Nervous System Stimulants; Humans; Narcolepsy | 2019 |
An interesting case of late age at onset of narcolepsy with cataplexy.
Topics: Amphetamine; Cataplexy; Central Nervous System Stimulants; Dextroamphetamine; Diagnosis, Differentia | 2014 |
Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding.
Topics: Adult; Amphetamine; Breast Feeding; Central Nervous System Stimulants; Child Development; Female; Hu | 2015 |
Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Analysis of Variance; Anima | 2010 |
[Clinical manifestations and therapy of narcolepsy].
Topics: Amphetamine; Amphetamines; Ephedrine; Humans; Narcolepsy; Sleep Wake Disorders | 1955 |
NARCOLEPSY. A DISCUSSION AND CASE PRESENTATION.
Topics: Amphetamine; Amphetamines; Cataplexy; Diagnosis, Differential; Genetics, Medical; Hallucinations; Hu | 1963 |
The influence of cardiazol and psychoton on the EEG in narcolepsy.
Topics: Amphetamine; Amphetamines; Electroencephalography; Humans; Narcolepsy; Pentylenetetrazole; Sleep Wak | 1954 |
[On the electrophysiologic evaluation of the effectiveness of phenamine and chlorazicin in patients with narcolepsy].
Topics: Adult; Amphetamine; Electrocardiography; Electroencephalography; Electromyography; Female; Humans; M | 1966 |
Amphetamine secretion in breast milk.
Topics: Adult; Amphetamine; Chromatography, Gas; Female; Humans; Infant; Milk, Human; Narcolepsy; Risk | 1984 |
Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
Topics: Amphetamine; Animals; Behavior, Animal; Benzhydryl Compounds; Cataplexy; Central Nervous System Stim | 1995 |
Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome.
Topics: Acoustic Stimulation; Adult; Amphetamine; Brain; Brain Mapping; Echo-Planar Imaging; Female; Humans; | 1996 |
General anesthesia in a patient on long-term amphetamine therapy: is there cause for concern?
Topics: Amphetamine; Androstanols; Anesthesia, General; Central Nervous System Stimulants; Emergency Medical | 2000 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Editorial: Narcolepsy.
Topics: Amphetamine; Female; Humans; Male; Narcolepsy; Sleep, REM | 1975 |
Amphetamines, growth hormone and narcolepsy.
Topics: Adult; Aged; Amphetamine; Arousal; Clomipramine; Dextroamphetamine; Drug Interactions; Drug Toleranc | 1977 |
Gradients of biogenic amine metabolites in cerebrospinal fluid.
Topics: Alzheimer Disease; Amphetamine; Brain Diseases; Brain Neoplasms; Depression; Homovanillic Acid; Huma | 1975 |
[Effect of imipramine, dexphenmetrazine and amphetamine sulfate on synchronous and paradoxical sleep in narcolepsy-cataplexy. A polygraphic study].
Topics: Amphetamine; Cataplexy; Electroencephalography; Humans; Imipramine; Narcolepsy; Phenmetrazine; Sleep | 1970 |
[2 kinds of sleep].
Topics: Amphetamine; Animals; Barbiturates; Cerebral Cortex; Dreams; Electroencephalography; Electromyograph | 1969 |
The influence of imipramine, dexphenmetrazine and amphetaminsulphate upon the clinical and polygraphic picture of narcolepsy-cataplexy.
Topics: Amphetamine; Cataplexy; Electrocardiography; Electroencephalography; Electromyography; Electrooculog | 1971 |
On the treatment of rapid eye movement narcolepsy.
Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Depression; Desipramine; Electroencephalograph | 1974 |
[Therapy of hypersomnia].
Topics: Amphetamine; Animals; Antidepressive Agents; Appetite Depressants; Bemegride; Caffeine; Cats; Centra | 1967 |
Treatment of narcolepsy.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Child; Humans; Narcolepsy | 1969 |
The influence of imipramine, dexphenmetrazine and amphetamine-sulphate on the composition of diurnal sleep of narcoleptics.
Topics: Amphetamine; Humans; Imipramine; Narcolepsy; Phenmetrazine; Sleep Stages; Time Factors | 1974 |
Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings.
Topics: Adult; Amphetamine; Aspartic Acid; Body Weight; Cataplexy; Cerebrospinal Fluid Proteins; Dextroamphe | 1974 |
Use of d-amphetamine and related central nervous system stimulants in children.
Topics: Adolescent; Amphetamine; Child; Drug and Narcotic Control; Humans; Hyperkinesis; Narcolepsy; Substan | 1973 |
Narcolepsy.
Topics: Accidents, Traffic; Adult; Amphetamine; Automobile Driving; Cataplexy; Female; Hallucinations; Human | 1974 |
Amphetamines, barbiturates, LSD and cannabis: their use and misuse.
Topics: Amphetamine; Barbiturates; Cannabis; Child Behavior Disorders; Crime; Depression; Humans; Hyperkines | 1970 |
[Gélineau's syndrome. Therapeutic action of neutral amphetamine sulfate].
Topics: Adult; Amphetamine; Humans; In Vitro Techniques; Narcolepsy; Sleep Wake Disorders | 1965 |